22nd Century Group (NASDAQ:XXII) Trading Down 1.1% – Should You Sell?

Shares of 22nd Century Group, Inc (NASDAQ:XXII) fell 1.1% on Monday . The stock traded as low as $4.21 and last traded at $4.2820. Approximately 4,405 shares changed hands during trading, a decline of 75% from the average daily volume of 17,823 shares. The stock had previously closed at $4.33.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of 22nd Century Group to a “sell” rating in a research note on Saturday, June 27th. Weiss Ratings downgraded 22nd Century Group from a “sell (e+)” rating to a “sell (e)” rating in a research note on Friday, July 10th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, 22nd Century Group presently has a consensus rating of “Sell”.

22nd Century Group Trading Down 3.8%

The stock has a market cap of $2.26 million, a price-to-earnings ratio of -0.00 and a beta of 0.67. The business’s fifty day simple moving average is $7.49 and its 200 day simple moving average is $74.85. The company has a debt-to-equity ratio of 0.02, a current ratio of 2.67 and a quick ratio of 2.12.

22nd Century Group (NASDAQ:XXII) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($5.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($24.00) by $18.93. 22nd Century Group had a negative net margin of 25.34% and a negative return on equity of 84.37%. The company had revenue of $4.11 million for the quarter, compared to analysts’ expectations of $4.61 million.

Hedge Funds Weigh In On 22nd Century Group

An institutional investor recently bought a new position in 22nd Century Group stock. Geode Capital Management LLC purchased a new position in shares of 22nd Century Group, Inc (NASDAQ:XXII) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 46,491 shares of the biotechnology company’s stock, valued at approximately $36,000. Geode Capital Management LLC owned 9.12% of 22nd Century Group at the end of the most recent quarter. Institutional investors and hedge funds own 18.06% of the company’s stock.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.